awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D
Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer
P2860
Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b78aab16e047c1da03a246f000aaad12d4e0302f
P2860
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)